TriangleMemantine -Twice Daily or Extended… (NCT05045950)
Memantine -Twice Daily or Extended Release trial for Brain Metastases (NCT05045950). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with measurable brain metastases from a solid cancer, no previous whole-brain radiation, and native English proficiency for cognitive testing. Blood cancers, leptomeningeal spread, and tumors treated with curative intent are excluded.
The idea: whole-brain radiation delivers thirty gray in ten daily treatments, divided into small pulses separated by pauses. Researchers test completion, tolerance, and cognitive decline. Oral memantine accompanies treatment for up to twenty-four weeks.
This phase 2 study plans 53 patients. Lindsay Puckett leads at the Medical College of Wisconsin; two Milwaukee sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.